Aurinia Pharmaceuticals Inc.
NASDAQ:AUPHBiotechnology
+$0.13 today
- Market cap
- $2.03B
- Beta
- 1.43
- P/E (TTM)
- 7.2
- EPS (TTM)
- $2.25
Volume 0.76M
Average 1.21M
AUPH Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Aurinia Pharmaceuticals Inc.NASDAQ: AUPH
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 239.3% from a year ago
Cash & equivalents stood at $179.83M at the end of Q2 FY2026, up 239.3% from a year earlier and up 338.5% from the prior quarter. Over 3 fiscal years it compounded at -5.2% a year.
Context
- Cash & equivalents amounted to 22.7% of total assets at the end of Q2 FY2026, up 12.2 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +239.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 80.21M USD
- Year-over-year change
- -3.9%
- 4-year CAGR
- -23.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 80.21M | -3.9% |
| FY2024 | 2024-12-31 | 83.43M | +70.7% |
| FY2023 | 2023-12-31 | 48.88M | -48.1% |
| FY2022 | 2022-12-31 | 94.17M | -59.4% |
| FY2021 | 2021-12-31 | 231.9M | — |
Cash & Equivalents vs competitors
How AUPH compares with its peers on the latest reported figures
- AUPH's Jun 2026 cash & equivalents of $179.83M is the 4th highest of the 10 companies compared; the peer median is $48.88M.
- Its year-over-year change of +239.3% is the 2nd highest of 8, against a peer median of -0.5%.
- Cash & equivalents amounts to 22.7% of total assets for AUPH, versus a peer median of 15.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $298.49M | +9.9% | +103.8% | 74.6% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $248.47M | — | — | 85.5% |
| Jun 2026 | $238.03M | +43.6% | +3.9% | 64.2% | |
| Jun 2026 | $179.83M | +239.3% | -5.2% | 22.7% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $63.71M | -58.0% | +51.8% | 11.4% |
| Jun 2026 | $48.88M | -0.5% | +101.3% | 9.2% | |
EVMNEvommune, Inc. | Mar 2026 | $48.32M | +747.1% | — | 15.0% |
| Jun 2026 | $32.83M | — | — | 25.6% | |
| Mar 2026 | $28.66M | -5.6% | -23.9% | 14.4% | |
| Mar 2026 | $6.15M | -27.6% | -26.1% | 4.2% | |
| Peer median (excluding AUPH) | $48.88M | -0.5% | +27.9% | 15.0% | |
Competitors are the stored peer set for AUPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 231.9M | 94.17M | 48.88M | 83.43M | 80.21M |
| Short-term Investments | 234.18M | 295.22M | 301.61M | 275.04M | 317.78M |
| Net Receivables | 15.41M | 13.48M | 24.09M | 36.54M | 41.45M |
| Inventory | 19.33M | 24.75M | 39.71M | 39.23M | 45.69M |
| Other Current Assets | 796K | 1.33M | 1.03M | 1.13M | 1.08M |
| Total Current Assets | 513.32M | 442.54M | 424.8M | 446.6M | 491.97M |
| Property, Plant & Equipment (Net) | 9.8M | 8.56M | 116.57M | 98.87M | 79.57M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 8.4M | 6.43M | 4.98M | 4.36M | 3.76M |
| Long-term Investments | 0 | 0 | 201K | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 176.19M |
| Other Non-current Assets | 11.84M | 13.34M | 1.52M | 823K | 93K |
| Total Non-current Assets | 30.04M | 28.32M | 123.26M | 104.05M | 259.62M |
| Total Assets | 543.37M | 470.86M | 548.06M | 550.65M | 751.59M |
| Account Payables | 3.88M | 3.09M | 4.33M | 5.19M | 3.31M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 814K | 625K | 667K | 0 | 0 |
| Deferred Revenue | 190K | 3.15M | 4.81M | 11M | 3.72M |
| Other Current Liabilities | 4.45M | 2.03M | 1.59M | 1.53M | 2.48M |
| Total Current Liabilities | 40.65M | 46.11M | 77.19M | 97.76M | 93.72M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 12.65M |
| Other Non-current Liabilities | 15.95M | 12.17M | 10.91M | 11.11M | 6.66M |
| Total Non-current Liabilities | 23.63M | 19.32M | 92.92M | 75.4M | 76.53M |
| Total Liabilities | 64.28M | 65.43M | 170.11M | 173.17M | 170.26M |
| Common Stock | 1.18B | 1.19B | 1.2B | 1.19B | 1.12B |
| Retained Earnings | (756.12M) | (864.3M) | (942.32M) | (936.57M) | (649.37M) |
| Accumulated OCI | (852K) | (1.06M) | (730K) | (647K) | (599K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 479.09M | 405.44M | 377.95M | 377.48M | 581.33M |
| Total Debt | 8.74M | 8.09M | 97.61M | 79.37M | 74.81M |
| Net Debt | (223.16M) | (86.08M) | 48.73M | (4.06M) | (5.4M) |
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
Intrinsic Alpha fair value
Locked
Current Price
$15.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.